Patent Number: 8,066,985

Title: Reovirus for the treatment of cellular proliferative disorders

Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.

Inventors: Lee; Patrick W. K. (Halifax, CA), Strong; James (Calgary, CA), Coffey; Matthew C. (Calgary, CA)

Assignee: Oncolytics Biotech Inc.

International Classification: A61K 49/00 (20060101); A61K 39/15 (20060101)

Expiration Date: 2020-11-29 0:00:00